Research
Hormonal
Glucagon-like peptide-1 (GLP-1) receptor agonists, specifically tirzepatide, significantly reduce AHI and improve hypoxic burden in patients with moderate-to-severe OSA and obesity, independent of or adjunct to CPAP use.
If you have moderate to severe sleep apnea and obesity, ask your doctor about Tirzepatide. Recent clinical trials show it significantly reduces breathing interruptions during sleep and improves oxygen levels, even for those already using CPAP. It has received FDA approval for this use. Be prepared for mild stomach issues initially, which usually subside.
StrongSupportsVERY_HIGH confidence
The change in AHI for those not on CPAP was −25.3±4.0 and −5.3±4.1 events·h−1 in the treatment and control cohorts, respectively, at 52 weeks ( p<0.001)... Tirzepatide has recently been approved by the FDA as the first drug for the treatment of moderate–severe OSA.
Why this rating
Based on a recently published RCT with strong statistical significance (p<0.001) and FDA approval.
Source
The role of weight management in sleep disordered breathing
William T. Griffin et al. · Breathe · 2025
narrative_reviewCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →